Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
68Ga-DOTA-NT-20.3
The First People's Hospital of Lianyungang
Pancreatic Ductal Adenocarcinoma
1 trial -
68Ga-Her2-affibody
The First People's Hospital of Lianyungang
Neoplasms
1 trial -
89Zr-KN035
The First People's Hospital of Lianyungang
Solid Tumor, Adult
1 trial -
99mTc-H7ND SPECT/CT imaging performed
The First People's Hospital of Lianyungang
NSCLC
1 trial -
A continuous intravenous infusion of 0.5-0.6 mg/kg/h Rocuronium Bromide Intravenous Solution (50 Mg/5 mL) to keep the target neuromuscular blockade (PTC = 1-2).
The First People's Hospital of Lianyungang
Neuromuscular Blockade
1 trial -
A single dose of liposomal bupivacaine is administered at the conclusion of surgery without adjunctive analgesics, followed by a supplemental dose 72 hours postoperatively.
The First People's Hospital of Lianyungang
Anal Fistula
1 trial -
ASC09/ritonavir group
The First People's Hospital of Lianyungang
2019-nCoV
1 trial -
ATRA+Venetoclax+Azacitidine
The First People's Hospital of Lianyungang
AML, Adult
1 trial -
Acalabrutinib
The First People's Hospital of Lianyungang
Chronic Lymphocytic Leukemia
1 trial -
Accurate Prediction Artificial Intelligence Models
The First People's Hospital of Lianyungang
Prostate Cancer
1 trial -
Adjustment of Antiplatelet Drugs
The First People's Hospital of Lianyungang
Intracranial Aneurysm
1 trial -
Albuterol
The First People's Hospital of Lianyungang
Chronic Obstructive Pulmonary Disease
1 trial -
Amberen
The First People's Hospital of Lianyungang
Climacteric Syndrome
1 trial -
Ambrisentan
The First People's Hospital of Lianyungang
Pulmonary Arterial Hypertension
1 trial -
Anlotinib Hydrochloride
The First People's Hospital of Lianyungang
Non-Small-Cell Lung
1 trial -
Anlotinib hydrochloride
The First People's Hospital of Lianyungang
Non-Small-Cell Lung Cancer
2 trials -
Anti-HER2 CAR-T cells
The First People's Hospital of Lianyungang
HER2-positive Advanced Malignant Solid Tumors
1 trial -
AntiPlatelet therapy
The First People's Hospital of Lianyungang
Coronary Artery Disease
1 trial -
Artificial Intelligence Enabled Transvaginal Ultrasound Imaging algorithm
The First People's Hospital of Lianyungang
Ovarian Cancer
1 trial -
Aspirin
The First People's Hospital of Lianyungang
Anterior Ischemic Optic Neuropathy
1 trial -
Atorvastatin
The First People's Hospital of Lianyungang
Contrast-induced Acute Kidney Injury
1 trial -
Atorvastatin 20 Mg Oral Tablet
The First People's Hospital of Lianyungang
Atherosclerotic Cardiovascular Disease
1 trial -
Atorvastatin Calcium 20Mg Tab
The First People's Hospital of Lianyungang
Hyperlipidemias
1 trial -
BCL regimen
The First People's Hospital of Lianyungang
Peripheral T-cell Lymphoma
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources